A Randomized, Single-Blind Study of Lansoprazole for the Prevention of Exacerbations of Chronic Obstructive Pulmonary Disease in Older Patients
OBJECTIVES: To investigate whether proton pump inhibitor (PPI) therapy reduces the frequency of common colds and exacerbations in patients with chronic obstructive pulmonary disease (COPD). DESIGN: Twelve‐month, randomized, observer‐blind, controlled trial. SETTING: A university hospital and three c...
Gespeichert in:
| Veröffentlicht in: | Journal of the American Geriatrics Society (JAGS) 2009-08, Vol.57 (8), p.1453-1457 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1457 |
|---|---|
| container_issue | 8 |
| container_start_page | 1453 |
| container_title | Journal of the American Geriatrics Society (JAGS) |
| container_volume | 57 |
| creator | Sasaki, Takahiko Nakayama, Katsutoshi Yasuda, Hiroyasu Yoshida, Motoki Asamura, Takaaki Ohrui, Takashi Arai, Hiroyuki Araya, Jun Kuwano, Kazuyoshi Yamaya, Mutsuo |
| description | OBJECTIVES: To investigate whether proton pump inhibitor (PPI) therapy reduces the frequency of common colds and exacerbations in patients with chronic obstructive pulmonary disease (COPD).
DESIGN: Twelve‐month, randomized, observer‐blind, controlled trial.
SETTING: A university hospital and three city hospitals in Miyagi prefecture in Japan.
PARTICIPANTS: One hundred patients with COPD (mean age ± SD 74.9 ± 8.2) participated. They were all ex‐smokers and had received conventional therapies for COPD, including smoking cessation and bronchodilators. Patients with gastroesophageal reflux disease or gastroduodenal ulcer were excluded.
INTERVENTION: Patients were randomly assigned to conventional therapies (control group) or conventional therapies plus PPI (lansoprazole 15 mg/d; PPI group) and observed for 12 months.
MEASUREMENTS: Frequency of common colds and COPD exacerbations.
RESULTS: The number of exacerbations per person in a year in the PPI group was significantly lower than that in the control group (0.34 ± 0.72 vs 1.18 ± 1.40; P |
| doi_str_mv | 10.1111/j.1532-5415.2009.02349.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67581743</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1810716221</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5599-47eaebe2f2fbd1c4e8876fd355e7031c53fa3e06c722b1b0f9663d0d39f6e30b3</originalsourceid><addsrcrecordid>eNqNkctuEzEUhkcIREPhFZCFBCsm-DKey4JFCSUFhaQiIKRuLI_nmDqd2MGeKUlfglfGQ6IgsQFvfPu-I_v8SYIIHpM4Xq3GhDOa8ozwMcW4GmPKsmq8vZeMjhf3kxHGmKZlTrKT5FEIK4wJxWX5MDkhFSecEDxKfp6hT9I2bm3uoHmJlsZ-ayF90xrboGXXNzvkNJpJG9zGyzvXAtLOo-4a0KWHW7CdcXZAzrdSga_lsA_DweTaO2sUWtSh873qzG1U-nbtrPQ79NYEkAGQsWjRNuDRZTRjtfA4eaBlG-DJYT5Nvrw7_zy5SGeL6fvJ2SxVnFdVmhUgoQaqqa4bojIoyyLXDeMcCsyI4kxLBjhXBaU1qbGu8pw1uGGVzoHhmp0mL_Z1N9597yF0Ym2CgraVFlwfRF7wkhQZ-ydIcVEyTqsIPvsLXLne2_gJQQlmRVkwEqFyDynvQvCgxcabdeyIIFgM0YqVGBIUQ4JiiFb8jlZso_r0UL-v19D8EQ9ZRuD5AZBByVZ7aZUJR46SEvPYoMi93nM_TAu7_36A-DBdDqvop3vfhA62R1_6m9g1VnDxdT4VHy9mV_Or2VxU7Bfobc-C</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>210378731</pqid></control><display><type>article</type><title>A Randomized, Single-Blind Study of Lansoprazole for the Prevention of Exacerbations of Chronic Obstructive Pulmonary Disease in Older Patients</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Sasaki, Takahiko ; Nakayama, Katsutoshi ; Yasuda, Hiroyasu ; Yoshida, Motoki ; Asamura, Takaaki ; Ohrui, Takashi ; Arai, Hiroyuki ; Araya, Jun ; Kuwano, Kazuyoshi ; Yamaya, Mutsuo</creator><creatorcontrib>Sasaki, Takahiko ; Nakayama, Katsutoshi ; Yasuda, Hiroyasu ; Yoshida, Motoki ; Asamura, Takaaki ; Ohrui, Takashi ; Arai, Hiroyuki ; Araya, Jun ; Kuwano, Kazuyoshi ; Yamaya, Mutsuo</creatorcontrib><description>OBJECTIVES: To investigate whether proton pump inhibitor (PPI) therapy reduces the frequency of common colds and exacerbations in patients with chronic obstructive pulmonary disease (COPD).
DESIGN: Twelve‐month, randomized, observer‐blind, controlled trial.
SETTING: A university hospital and three city hospitals in Miyagi prefecture in Japan.
PARTICIPANTS: One hundred patients with COPD (mean age ± SD 74.9 ± 8.2) participated. They were all ex‐smokers and had received conventional therapies for COPD, including smoking cessation and bronchodilators. Patients with gastroesophageal reflux disease or gastroduodenal ulcer were excluded.
INTERVENTION: Patients were randomly assigned to conventional therapies (control group) or conventional therapies plus PPI (lansoprazole 15 mg/d; PPI group) and observed for 12 months.
MEASUREMENTS: Frequency of common colds and COPD exacerbations.
RESULTS: The number of exacerbations per person in a year in the PPI group was significantly lower than that in the control group (0.34 ± 0.72 vs 1.18 ± 1.40; P<.001). The adjusted odds ratio with logistic regression for having exacerbation (≥once/year) in the PPI group compared with the control group was 0.23 (P=.004). In contrast, there was no significant difference in the numbers of common colds per person per year between the PPI group and the control group (1.22 ± 2.09 vs 2.04 ± 3.07; P=.12). PPI therapy significantly reduced the risk of catching frequent common colds (≥3 times/year), the adjusted odds ratio of which was 0.28 (P=.048).
CONCLUSION: In this single‐blind, nonplacebo‐controlled trial, lansoprazole was associated with a significant decrease in COPD exacerbations. More definitive clinical trials are warranted.</description><identifier>ISSN: 0002-8614</identifier><identifier>EISSN: 1532-5415</identifier><identifier>DOI: 10.1111/j.1532-5415.2009.02349.x</identifier><identifier>PMID: 19515110</identifier><identifier>CODEN: JAGSAF</identifier><language>eng</language><publisher>Malden, USA: Blackwell Publishing Inc</publisher><subject>2-Pyridinylmethylsulfinylbenzimidazoles - therapeutic use ; Aged ; Anti-Infective Agents - therapeutic use ; Biological and medical sciences ; Chronic obstructive pulmonary disease ; Clinical trials ; Colds ; common cold ; Common Cold - drug therapy ; Drug therapy ; exacerbation ; Female ; General aspects ; Humans ; Japan ; Lansoprazole ; Logistic Models ; lower airway infection ; Male ; Medical sciences ; Miscellaneous ; Older people ; Prevention and actions ; Preventive medicine ; proton pump inhibitor ; Public health. Hygiene ; Public health. Hygiene-occupational medicine ; Pulmonary Disease, Chronic Obstructive - drug therapy ; Pulmonary Disease, Chronic Obstructive - physiopathology ; Single-Blind Method ; Treatment Outcome</subject><ispartof>Journal of the American Geriatrics Society (JAGS), 2009-08, Vol.57 (8), p.1453-1457</ispartof><rights>2009, Copyright the Authors. Journal compilation © 2009, The American Geriatrics Society</rights><rights>2009 INIST-CNRS</rights><rights>Journal compilation 2009 The American Geriatrics Society/Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5599-47eaebe2f2fbd1c4e8876fd355e7031c53fa3e06c722b1b0f9663d0d39f6e30b3</citedby><cites>FETCH-LOGICAL-c5599-47eaebe2f2fbd1c4e8876fd355e7031c53fa3e06c722b1b0f9663d0d39f6e30b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1532-5415.2009.02349.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1532-5415.2009.02349.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21805355$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19515110$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sasaki, Takahiko</creatorcontrib><creatorcontrib>Nakayama, Katsutoshi</creatorcontrib><creatorcontrib>Yasuda, Hiroyasu</creatorcontrib><creatorcontrib>Yoshida, Motoki</creatorcontrib><creatorcontrib>Asamura, Takaaki</creatorcontrib><creatorcontrib>Ohrui, Takashi</creatorcontrib><creatorcontrib>Arai, Hiroyuki</creatorcontrib><creatorcontrib>Araya, Jun</creatorcontrib><creatorcontrib>Kuwano, Kazuyoshi</creatorcontrib><creatorcontrib>Yamaya, Mutsuo</creatorcontrib><title>A Randomized, Single-Blind Study of Lansoprazole for the Prevention of Exacerbations of Chronic Obstructive Pulmonary Disease in Older Patients</title><title>Journal of the American Geriatrics Society (JAGS)</title><addtitle>J Am Geriatr Soc</addtitle><description>OBJECTIVES: To investigate whether proton pump inhibitor (PPI) therapy reduces the frequency of common colds and exacerbations in patients with chronic obstructive pulmonary disease (COPD).
DESIGN: Twelve‐month, randomized, observer‐blind, controlled trial.
SETTING: A university hospital and three city hospitals in Miyagi prefecture in Japan.
PARTICIPANTS: One hundred patients with COPD (mean age ± SD 74.9 ± 8.2) participated. They were all ex‐smokers and had received conventional therapies for COPD, including smoking cessation and bronchodilators. Patients with gastroesophageal reflux disease or gastroduodenal ulcer were excluded.
INTERVENTION: Patients were randomly assigned to conventional therapies (control group) or conventional therapies plus PPI (lansoprazole 15 mg/d; PPI group) and observed for 12 months.
MEASUREMENTS: Frequency of common colds and COPD exacerbations.
RESULTS: The number of exacerbations per person in a year in the PPI group was significantly lower than that in the control group (0.34 ± 0.72 vs 1.18 ± 1.40; P<.001). The adjusted odds ratio with logistic regression for having exacerbation (≥once/year) in the PPI group compared with the control group was 0.23 (P=.004). In contrast, there was no significant difference in the numbers of common colds per person per year between the PPI group and the control group (1.22 ± 2.09 vs 2.04 ± 3.07; P=.12). PPI therapy significantly reduced the risk of catching frequent common colds (≥3 times/year), the adjusted odds ratio of which was 0.28 (P=.048).
CONCLUSION: In this single‐blind, nonplacebo‐controlled trial, lansoprazole was associated with a significant decrease in COPD exacerbations. More definitive clinical trials are warranted.</description><subject>2-Pyridinylmethylsulfinylbenzimidazoles - therapeutic use</subject><subject>Aged</subject><subject>Anti-Infective Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Chronic obstructive pulmonary disease</subject><subject>Clinical trials</subject><subject>Colds</subject><subject>common cold</subject><subject>Common Cold - drug therapy</subject><subject>Drug therapy</subject><subject>exacerbation</subject><subject>Female</subject><subject>General aspects</subject><subject>Humans</subject><subject>Japan</subject><subject>Lansoprazole</subject><subject>Logistic Models</subject><subject>lower airway infection</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Miscellaneous</subject><subject>Older people</subject><subject>Prevention and actions</subject><subject>Preventive medicine</subject><subject>proton pump inhibitor</subject><subject>Public health. Hygiene</subject><subject>Public health. Hygiene-occupational medicine</subject><subject>Pulmonary Disease, Chronic Obstructive - drug therapy</subject><subject>Pulmonary Disease, Chronic Obstructive - physiopathology</subject><subject>Single-Blind Method</subject><subject>Treatment Outcome</subject><issn>0002-8614</issn><issn>1532-5415</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkctuEzEUhkcIREPhFZCFBCsm-DKey4JFCSUFhaQiIKRuLI_nmDqd2MGeKUlfglfGQ6IgsQFvfPu-I_v8SYIIHpM4Xq3GhDOa8ozwMcW4GmPKsmq8vZeMjhf3kxHGmKZlTrKT5FEIK4wJxWX5MDkhFSecEDxKfp6hT9I2bm3uoHmJlsZ-ayF90xrboGXXNzvkNJpJG9zGyzvXAtLOo-4a0KWHW7CdcXZAzrdSga_lsA_DweTaO2sUWtSh873qzG1U-nbtrPQ79NYEkAGQsWjRNuDRZTRjtfA4eaBlG-DJYT5Nvrw7_zy5SGeL6fvJ2SxVnFdVmhUgoQaqqa4bojIoyyLXDeMcCsyI4kxLBjhXBaU1qbGu8pw1uGGVzoHhmp0mL_Z1N9597yF0Ym2CgraVFlwfRF7wkhQZ-ydIcVEyTqsIPvsLXLne2_gJQQlmRVkwEqFyDynvQvCgxcabdeyIIFgM0YqVGBIUQ4JiiFb8jlZso_r0UL-v19D8EQ9ZRuD5AZBByVZ7aZUJR46SEvPYoMi93nM_TAu7_36A-DBdDqvop3vfhA62R1_6m9g1VnDxdT4VHy9mV_Or2VxU7Bfobc-C</recordid><startdate>200908</startdate><enddate>200908</enddate><creator>Sasaki, Takahiko</creator><creator>Nakayama, Katsutoshi</creator><creator>Yasuda, Hiroyasu</creator><creator>Yoshida, Motoki</creator><creator>Asamura, Takaaki</creator><creator>Ohrui, Takashi</creator><creator>Arai, Hiroyuki</creator><creator>Araya, Jun</creator><creator>Kuwano, Kazuyoshi</creator><creator>Yamaya, Mutsuo</creator><general>Blackwell Publishing Inc</general><general>Wiley-Blackwell</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7U1</scope><scope>7U2</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>200908</creationdate><title>A Randomized, Single-Blind Study of Lansoprazole for the Prevention of Exacerbations of Chronic Obstructive Pulmonary Disease in Older Patients</title><author>Sasaki, Takahiko ; Nakayama, Katsutoshi ; Yasuda, Hiroyasu ; Yoshida, Motoki ; Asamura, Takaaki ; Ohrui, Takashi ; Arai, Hiroyuki ; Araya, Jun ; Kuwano, Kazuyoshi ; Yamaya, Mutsuo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5599-47eaebe2f2fbd1c4e8876fd355e7031c53fa3e06c722b1b0f9663d0d39f6e30b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>2-Pyridinylmethylsulfinylbenzimidazoles - therapeutic use</topic><topic>Aged</topic><topic>Anti-Infective Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Chronic obstructive pulmonary disease</topic><topic>Clinical trials</topic><topic>Colds</topic><topic>common cold</topic><topic>Common Cold - drug therapy</topic><topic>Drug therapy</topic><topic>exacerbation</topic><topic>Female</topic><topic>General aspects</topic><topic>Humans</topic><topic>Japan</topic><topic>Lansoprazole</topic><topic>Logistic Models</topic><topic>lower airway infection</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Miscellaneous</topic><topic>Older people</topic><topic>Prevention and actions</topic><topic>Preventive medicine</topic><topic>proton pump inhibitor</topic><topic>Public health. Hygiene</topic><topic>Public health. Hygiene-occupational medicine</topic><topic>Pulmonary Disease, Chronic Obstructive - drug therapy</topic><topic>Pulmonary Disease, Chronic Obstructive - physiopathology</topic><topic>Single-Blind Method</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sasaki, Takahiko</creatorcontrib><creatorcontrib>Nakayama, Katsutoshi</creatorcontrib><creatorcontrib>Yasuda, Hiroyasu</creatorcontrib><creatorcontrib>Yoshida, Motoki</creatorcontrib><creatorcontrib>Asamura, Takaaki</creatorcontrib><creatorcontrib>Ohrui, Takashi</creatorcontrib><creatorcontrib>Arai, Hiroyuki</creatorcontrib><creatorcontrib>Araya, Jun</creatorcontrib><creatorcontrib>Kuwano, Kazuyoshi</creatorcontrib><creatorcontrib>Yamaya, Mutsuo</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>Risk Abstracts</collection><collection>Safety Science and Risk</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the American Geriatrics Society (JAGS)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sasaki, Takahiko</au><au>Nakayama, Katsutoshi</au><au>Yasuda, Hiroyasu</au><au>Yoshida, Motoki</au><au>Asamura, Takaaki</au><au>Ohrui, Takashi</au><au>Arai, Hiroyuki</au><au>Araya, Jun</au><au>Kuwano, Kazuyoshi</au><au>Yamaya, Mutsuo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Randomized, Single-Blind Study of Lansoprazole for the Prevention of Exacerbations of Chronic Obstructive Pulmonary Disease in Older Patients</atitle><jtitle>Journal of the American Geriatrics Society (JAGS)</jtitle><addtitle>J Am Geriatr Soc</addtitle><date>2009-08</date><risdate>2009</risdate><volume>57</volume><issue>8</issue><spage>1453</spage><epage>1457</epage><pages>1453-1457</pages><issn>0002-8614</issn><eissn>1532-5415</eissn><coden>JAGSAF</coden><abstract>OBJECTIVES: To investigate whether proton pump inhibitor (PPI) therapy reduces the frequency of common colds and exacerbations in patients with chronic obstructive pulmonary disease (COPD).
DESIGN: Twelve‐month, randomized, observer‐blind, controlled trial.
SETTING: A university hospital and three city hospitals in Miyagi prefecture in Japan.
PARTICIPANTS: One hundred patients with COPD (mean age ± SD 74.9 ± 8.2) participated. They were all ex‐smokers and had received conventional therapies for COPD, including smoking cessation and bronchodilators. Patients with gastroesophageal reflux disease or gastroduodenal ulcer were excluded.
INTERVENTION: Patients were randomly assigned to conventional therapies (control group) or conventional therapies plus PPI (lansoprazole 15 mg/d; PPI group) and observed for 12 months.
MEASUREMENTS: Frequency of common colds and COPD exacerbations.
RESULTS: The number of exacerbations per person in a year in the PPI group was significantly lower than that in the control group (0.34 ± 0.72 vs 1.18 ± 1.40; P<.001). The adjusted odds ratio with logistic regression for having exacerbation (≥once/year) in the PPI group compared with the control group was 0.23 (P=.004). In contrast, there was no significant difference in the numbers of common colds per person per year between the PPI group and the control group (1.22 ± 2.09 vs 2.04 ± 3.07; P=.12). PPI therapy significantly reduced the risk of catching frequent common colds (≥3 times/year), the adjusted odds ratio of which was 0.28 (P=.048).
CONCLUSION: In this single‐blind, nonplacebo‐controlled trial, lansoprazole was associated with a significant decrease in COPD exacerbations. More definitive clinical trials are warranted.</abstract><cop>Malden, USA</cop><pub>Blackwell Publishing Inc</pub><pmid>19515110</pmid><doi>10.1111/j.1532-5415.2009.02349.x</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-8614 |
| ispartof | Journal of the American Geriatrics Society (JAGS), 2009-08, Vol.57 (8), p.1453-1457 |
| issn | 0002-8614 1532-5415 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67581743 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | 2-Pyridinylmethylsulfinylbenzimidazoles - therapeutic use Aged Anti-Infective Agents - therapeutic use Biological and medical sciences Chronic obstructive pulmonary disease Clinical trials Colds common cold Common Cold - drug therapy Drug therapy exacerbation Female General aspects Humans Japan Lansoprazole Logistic Models lower airway infection Male Medical sciences Miscellaneous Older people Prevention and actions Preventive medicine proton pump inhibitor Public health. Hygiene Public health. Hygiene-occupational medicine Pulmonary Disease, Chronic Obstructive - drug therapy Pulmonary Disease, Chronic Obstructive - physiopathology Single-Blind Method Treatment Outcome |
| title | A Randomized, Single-Blind Study of Lansoprazole for the Prevention of Exacerbations of Chronic Obstructive Pulmonary Disease in Older Patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T20%3A31%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Randomized,%20Single-Blind%20Study%20of%20Lansoprazole%20for%20the%20Prevention%20of%20Exacerbations%20of%20Chronic%20Obstructive%20Pulmonary%20Disease%20in%20Older%20Patients&rft.jtitle=Journal%20of%20the%20American%20Geriatrics%20Society%20(JAGS)&rft.au=Sasaki,%20Takahiko&rft.date=2009-08&rft.volume=57&rft.issue=8&rft.spage=1453&rft.epage=1457&rft.pages=1453-1457&rft.issn=0002-8614&rft.eissn=1532-5415&rft.coden=JAGSAF&rft_id=info:doi/10.1111/j.1532-5415.2009.02349.x&rft_dat=%3Cproquest_cross%3E1810716221%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=210378731&rft_id=info:pmid/19515110&rfr_iscdi=true |